NEOGENOMICS INC — Director's Dealing 2018

May 30, 2018

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: NEOGENOMICS INC (NEO)
CIK: 0001077183
Period of Report: 2018-05-25

Reporting Person: BALLIET JENNIFER (VP and Chief Culture Officer)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2018-05-25	Common Stock	M	6666	—	Acquired	6666	Direct

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2018-05-25	Restricted Stock	$0.0	M	6666	Disposed		Common Stock (6666.0)	Direct

Holdings (Derivative)

Security	Exercise Price	Expiration	Underlying	Shares	Ownership
Stock Option (Right to Buy)	$4.78	2020-05-04	Common Stock (100000.0)	100000	Direct
Stock Option (Right to Buy)	$7.15	2021-04-20	Common Stock (50000.0)	50000	Direct
Stock Option (Right to Buy)	$7.52	2022-04-28	Common Stock (60000.0)	60000	Direct
Stock Option (Right to Buy)	$8.03	2023-02-26	Common Stock (72500.0)	72500	Direct

Footnotes

F1: On May 4, 2015, Jennifer Balliet was granted 120,000 stock options. The options vest ratably over the first three anniversary dates of the grant date.

F2: On April 20, 2016, Jennifer Balliet was granted 50,000 stock options. These options vest ratably over the first three anniversary dates of the grant date.

F3: On April 28, 2017, Jennifer Balliet was granted 60,000 stock options. The options vest ratably over the first three anniversaries of the grant date.

F4: Each share of restricted stock represents the contingent right to receive one share of common stock upon vesting.

F5: Restricted stock will vest as follows; 6,666 units vested on May 25, 2018 and 6,667 units will vest on May 25, 2019 and 2020.

F6: These restricted stock will terminate upon the earliest of death, termination of employment or the last vesting date.

F7: On February 26, 2018, Jennifer Balliet was granted 72,500 stock options which vested ratably over the first three anniversary dates of the grant date.